- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05593120
Evaluation of Health Economics for Noninvasive Coronary Fractional Flow Reserve Measurement Technology
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The 2021 ACC/AHA Guidelines now highlight use of CT-FFR as a front-line pathway to help in "the diagnosis of vessel-specific ischemia and to guide decision-making regarding the use of coronary revascularization". Previous observational PLATFORM study, which compared the use of CT-FFR with standard assessment of patients with stable chest pain enrolled from 11 European sites, demonstrated that management based on CT-FFR was both safe and associated with a significantly lower frequency of invasive angiograms demonstrating no significant coronary artery disease (CAD). Furthermore, the CT-FFR strategy appeared to be economically attractive in this observational study, and was supported by the 2016 National Institute for Health and Care Excellence (NICE) guidance. In contrast, the FORECAST randomized trial included 1400 patients with stable chest pain from 11 centres in the UK, and the results showed that a strategy of CCTA with selective CT-FFR in patients with stable angina did not differ significantly from standard clinical care pathways in cost or clinical outcomes, but did reduce the use of invasive coronary angiography. As abovementioned, the population enrolled in the previous studies were from different western countries, and the cost analysis results of CT-FFR application in different countries are diverse in terms of health care economics.
To date, however, the cost-effectiveness and clinical safety impact of using CT-FFR instead of other tests in the initial evaluation of patients with suspected coronary artery disease has not been tested in a prospective clinical trial in China.
The OVERALL OBJECTVE of this prospective, observational study is to compare resource utilization, time-effectiveness and clinical safety in subjects with suspected CAD receiving standard practice evaluation and treatment versus subjects receiving CT-FFR-guided evaluation and treatment in order to further inform patients, health care providers, and other stakeholders about which technologies are most cost-effective and efficient in the diagnosis of CAD. The hypothesis this CERTAIN trial is that CT-FFR would be associated with (1) lower overall costs; (2) shorter time period between initial consultation and definitive management plan; (3) better patient experience.
The 2 strategies for the CERTAIN trial are:
[A] TEST GROUP: All patients will be assessed and managed according to the results of CT-FFR test, assuming they have no prespecified contraindications to CT coronary angiography. The result of the CT-FFR will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
[B] REFERENCE GROUP: All patients will be assessed and managed exactly as they are usually treated by the investigator and the institution's heart team according to standard practice in Wuhan Asia Heart Hospital.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Xiaojing Ma
- Phone Number: 15902751799
- Email: xjm9027581@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Wuhan Asia Heart Hospital
-
Contact:
- Xiaojing Ma
- Phone Number: 15902751799
- Email: xjm9027581@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged over 18
- Providing written informed consent
- No contraindication to CTA
- At least 1 lesion with a percent diameter stenosis (DS%) 30%-90% in a coronary artery with a ≥2.0 mm reference vessel diameter diagnosed on coronary CTA
Exclusion Criteria:
- Acute coronary syndrome or myocardial infarction requiring urgent revascularization
- Prior PCI or CABG surgery
- Allergic to contrast
- BMI>35 at the time of coronary CTA
- Advanced renal impairment
- Significant valve disease (severe aortic stenosis or regurgitation; severe mitral regurgitation)
- Life expectancy <12 months
- Repeated enrollment
- Any other factors that the researchers consider not suitable for inclusion or completion of this study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CT-FFR
All patients will be assessed and managed according to the results of CT-FFR test, assuming they have no prespecified contraindications to CT coronary angiography.
The result of the CT-FFR will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
|
In the test group all patients who are eligible for CTA will undergo CTA as their default test.
Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR.
In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels.
CT-FFR will be evaluated in a blinded fashion with a "Coarse-to-Fine Subpixel" algorithm for lumen contour.
The data derived from this test will determine their management strategy.
|
Routine care
All patients will be assessed and managed exactly as they are usually treated by the investigator and the institution's heart team according to routine practice in Wuhan Asia Heart Hospital.
|
All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital.
The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resource utilisation
Time Frame: 6 months
|
To determine whether, in a Chinese population of patients presenting to Wuhan Asia Heart Hospital, CT-FFR as a default test is noninferior in terms of total costs when compared to routine clinical pathway recommended by the investigator and the institution's heart team.
Comparison of resource utilization between two groups at 180 days (+30/-15 days).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time period between initial consultation and definitive management plan
Time Frame: 6 months
|
Comparison of time period between initial consultation and definitive management plan between two groups during 180 days (+30/-15 days).
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xiaojing Ma, Wuhan Asia Heart Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Health Economics
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on CT-FFR
-
Northwell HealthToshiba America Medical Systems, Inc.Enrolling by invitationCoronary Artery Disease | Chest Pain | Acute Coronary Syndrome | Acute Myocardial InfarctionUnited States
-
Northwell HealthHeartFlow, Inc.CompletedAngina, Stable Chest Pain
-
Toshiba Medical Systems Corporation, JapanCompleted
-
Chinese PLA General HospitalTongji Hospital; Qilu Hospital of Shandong University; Second Affiliated Hospital... and other collaboratorsUnknownCoronary Artery DiseaseChina
-
St. Antonius HospitalUMC Utrecht; ZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingCoronary Artery DiseaseNetherlands
-
Seoul National University HospitalSeverance Hospital; Keimyung University Dongsan Medical Center; Chosun University... and other collaboratorsCompletedCoronary Artery DiseaseKorea, Republic of
-
Beijing HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...Recruiting
-
Stanford UniversitySiemens Medical SolutionsTerminatedCoronary Artery Disease | Computed TomographyUnited States
-
St. Olavs HospitalNorwegian University of Science and TechnologyCompleted
-
Rigshospitalet, DenmarkRecruitingCardiovascular Diseases | Coronary Artery Disease | Heart Failure | Stroke | Acute Myocardial Infarction | Chest SyndromeDenmark